Publicaciones en las que colabora con Aleix Prat (25)

2024

  1. Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy

    npj Breast Cancer, Vol. 10, Núm. 1

  2. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

    ESMO Open, Vol. 9, Núm. 3

2023

  1. Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer

    Nature Communications, Vol. 14, Núm. 1

  2. HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer

    Frontiers in Oncology, Vol. 13

  3. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

    Annals of Oncology, Vol. 34, Núm. 8, pp. 670-680

  4. Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis

    ESMO Open, Vol. 8, Núm. 3

2022

  1. Gene expression profiles of breast cancer metastasis according to organ site

    Molecular Oncology, Vol. 16, Núm. 1, pp. 69-87

  2. Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial

    European Journal of Cancer, Vol. 174, pp. 232-242

2021

  1. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

    The Lancet Oncology, Vol. 22, Núm. 4, pp. 489-498

  2. COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry

    Therapeutic Advances in Medical Oncology, Vol. 13

  3. Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy

    npj Breast Cancer, Vol. 7, Núm. 1

  4. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

    Annals of Oncology, Vol. 32, Núm. 10, pp. 1216-1235

  5. First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study

    Frontiers in Oncology, Vol. 11

  6. Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT

    EBioMedicine, Vol. 69

  7. SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

    Frontiers in Oncology, Vol. 11

2020

  1. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

    The Lancet Oncology, Vol. 21, Núm. 11, pp. 1455-1464

  2. A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone receptor-positive HER2-negative breast cancer

    Clinical Cancer Research, Vol. 26, Núm. 23, pp. 6141-6148

  3. Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial

    Clinical Cancer Research, Vol. 26, Núm. 22, pp. 5820-5829

  4. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

    Breast Cancer Research, Vol. 22, Núm. 1

  5. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

    Nature Communications, Vol. 11, Núm. 1